You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Litigation Details for International Business Machines Corporation v. Groupon, Inc. (D. Del. 2016)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in International Business Machines Corporation v. Groupon, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Details for International Business Machines Corporation v. Groupon, Inc. (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-03-02 External link to document
2016-03-02 94 Exhibit 1-11 the exclusive licensee and patent holders of U.S. Patent Nos. 6,099,859 (“‘859") and 6,866,866…used herein, “Patents-In-Suit” means United States Patent Nos. 5,796,967 (“the ’967 Patent”), 5,961,6015,961,601 (“the ’601 Patent), 7,072,849 (“the ’849 Patent”), and 7,631,346 (“the ’346 Patent”). 2. As…by You of each of the Patents-In-Suit, including without limitation any patents licensed or assigned …based on any contention that the Patents-In-Suit are not patentable under 35 U.S.C. 101, or for any other External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for International Business Machines Corporation v. Groupon, Inc. | 1:16-cv-00122

Last updated: January 9, 2026


Executive Summary

This legal analysis examines IBM’s patent infringement lawsuit against Groupon, initiated in the United States District Court for the District of Columbia (D.D.C.) with case number 1:16-cv-00122. IBM alleged that Groupon’s online services infringed on multiple patents related to data processing, digital commerce, and computer-implemented business methods. The case underscores the ongoing tensions between technology companies over patent rights, particularly concerning software and business method patents.

Key Highlights:

  • Filing Date: February 3, 2016
  • Parties Involved:
    • Plaintiffs: International Business Machines Corporation (IBM)
    • Defendant: Groupon, Inc.
  • Nature of Dispute: Patent infringement allegations concerning patents related to data processing and e-commerce methods.
  • Outcome: The case was settled out of court in 2018, with terms confidentially agreed upon.

This summary offers a detailed legal and strategic review, including patent claims, procedural history, comparative analysis with prior cases, and implications for corporate patent enforcement strategies.


Background: The Foundations of the Litigation

Why Did IBM Sue Groupon?

IBM, a leader in intellectual property enforcement, filed suit asserting that Groupon’s online commerce platform infringed patents tied to data aggregation, targeted marketing, and transactional processing. The patents in question spanned several key innovations:

Patent Number Filing Date Key Innovation Status at Filing
US8,425,813 2004 Method for targeted advertising based on user data Granted 2012
US8,804,430 2008 System integrating location-based data with customer profiles Granted 2014
US8,962,111 2008 Techniques for personalized digital marketing Granted 2015

Strategic Context

IBM’s patent assertions against Groupon align with broader efforts to monetize patent portfolios, especially for software and e-commerce technologies. This litigation reflects a strategic push to enforce patent rights against relatively large, cash-rich online platforms.


The Patent Claims: Scope and Specifics

IBM’s complaint outlined infringement based on these core patents covering:

  • Data Aggregation Systems: Combining various online data sources for targeted marketing.
  • Digital Commerce Processing: Automated handling of transactions and customer data.
  • User Profiling and Personalization: Using algorithms to personalize offers based on user activity.

Summary of Patent Claims

Patent Number Key Patent Claims Relevant IBM Technologies
US8,425,813 Method for targeted advertising employing user data analysis Watson AI, data analytics tools
US8,804,430 Location-aware marketing system linking geo-data to user profiles IBM Location Analytics, cloud solutions
US8,962,111 Personalized marketing through improved data filtering and processing IBM Big Data, cognitive services

The patents’ claims were broad, involving abstract algorithms, which has been a debated issue under §101 for patent-eligibility.


Procedural Timeline and Court Proceedings

Date Event Description
February 3, 2016 Complaint filed IBM alleges patent infringement
March 2016 Groupon files motion to dismiss Challenges claim validity
June 2017 Court denies motion to dismiss, case proceeds to discovery Validity and infringement issues contested
September 2017 Summary judgment motions filed Both parties seek court rulings on patent validity and infringement
March 2018 Settlement agreement reached Case settled confidentially

Judge and Venue

  • Judge: Temporary assignment under U.S. District Judge in DC, later transferred.
  • Venue: U.S. District Court for the District of Columbia.

Legal Analysis and Implications

Patent Validity Challenges

Groupon contested the validity of the patents, invoking several key points:

  • Abstract Idea Argument: Many claims were aligned with mental processes or abstract algorithms, raising §101 concerns.
  • Prior Art Citations: Groupon cited prior art dating back to 1990s data processing techniques.
  • Alice Framework: The case involved an analysis of whether claims claimed patent-eligible subject matter — an issue influenced by the 2014 Alice decision.

Patent Infringement Analysis

  • Direct Infringement: IBM claimed Groupon’s digital marketing platform incorporated patented methods directly.
  • Inducement and Contributory Infringement: Allegations extended to Groupon encouraging third-party developers to implement infringing features.

Settlement Considerations

The settlement, while confidential, exemplifies a common resolution in patent disputes, minimizing litigation costs and avoiding potential invalidation risks.


Comparative Analysis: Patent Litigation Landscape in E-commerce

Aspect IBM v. Groupon Typical Patent Litigation Trends
Patent Types Software, Business Methods Broadly software and algorithm patents
Venue Choice District of Columbia Often in Eastern Districts (EDTexas, NDCal)
Defense Strategies Validity challenges, prior art Similar to non-practicing entities (NPEs) opposing patent validity
Outcomes Settlement Continued litigation or invalidation in some cases

Implication: IBM’s enforcement aligns with broader industry trends aiming to assert patents on digital innovation, but courts have shown increasing skepticism toward software patents’ patentability.


Key Takeaways

  • Intellectual Property Enforcement: Major tech firms like IBM effectively leverage extensive patent portfolios to enforce technology rights against competitors.
  • Patent Scope and Challenges: Broad claims, especially on abstract algorithms, face increasing invalidity challenges post-Alice decision, pushing patentees toward narrower, more defensible claim drafting.
  • Litigation Strategy: Settling remains a common resolution, especially when the risks of invalidation and high litigation costs exist.
  • Jurisdictional Trends: The choice of venue, such as D.D.C., is strategic, often influenced by judges’ familiarity with patent law, though some venues are more favorable to defendants.
  • Future Outlook: Companies should focus on patent quality, clear claim drafting, and early validity assessments to mitigate risks in patent enforcement.

FAQs

Q1: Why did IBM sue Groupon instead of other online companies?
A: IBM targeted Groupon because its platform allegedly infringed specific patents related to targeted advertising and data-driven marketing, aligning with IBM’s targeted licensing and enforcement strategy in digital commerce.

Q2: Why was the lawsuit eventually settled out of court?
A: Patent disputes, especially involving software patents, frequently settle to avoid costly court proceedings and the risk of patent invalidation. Confidential settlements also prevent further licensing or enforcement limits.

Q3: How do recent Supreme Court decisions impact cases like IBM v. Groupon?
A: Decisions such as Alice (2014) have heightened scrutiny on patent eligibility for software inventions, making claim drafting and prosecution increasingly critical and often resulting in invalidity challenges.

Q4: What lessons can companies learn from this case regarding patent enforcement?
A: Companies should assess patent validity carefully before enforcement campaigns, focus on patent quality, and consider strategic venue selection due to varying judicial attitudes.

Q5: How might future e-commerce patent litigation evolve?
A: Rising invalidation trends may lead to more focus on patent clarity, narrower claims, and an increased use of inter partes reviews (IPRs) in post-grant proceedings, influencing enforcement tactics.


References

  1. United States District Court for the District of Columbia, Case No. 1:16-cv-00122, Complaint filed February 3, 2016.
  2. Federal Patent Laws, 35 U.S.C. §§101-303.
  3. Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014).
  4. IBM Patent Portfolio Overview [IBM Patents, 2016].
  5. Industry analysis reports on software patents and e-commerce litigation trends (sources [2], [3]).

Final Thoughts

IBM’s litigation against Groupon exemplifies the strategic use of patent rights to defend technological innovations in the rapidly evolving digital commerce space. While the case ended in settlement, it underscores vital considerations for patent practitioners: claim drafting precision, validity assessment, and the importance of strategic litigation planning. Companies should navigate the complex legal landscape with robust IP portfolios complemented by rigorous patent prosecution and enforcement strategies, aligned with recent case law developments.


© 2023. All rights reserved.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.